Matthew Richard Crittall

Title: Matthew Richard Crittall: Innovator in GLP-1 Receptor Modulation

Introduction

Matthew Richard Crittall is a notable inventor based in Nottinghamshire, GB. He has made significant contributions to the field of pharmacology, particularly in the modulation of the glucagon-like peptide 1 (GLP-1) receptor. His work has implications for various therapeutic applications, especially in the treatment of metabolic disorders.

Latest Patents

Crittall holds a patent for GLP-1 receptor modulators. The patent describes compounds that modulate the GLP-1 receptor, along with products containing such compounds and methods for their use and synthesis. These compounds are characterized by a specific structure, as outlined in Formula (I), or their pharmaceutically acceptable salts.

Career Highlights

Crittall is associated with Receptos, Inc., where he has been instrumental in advancing research related to GLP-1 receptor modulation. His innovative approach has led to the development of new therapeutic strategies that could benefit patients with metabolic conditions.

Collaborations

Crittall has collaborated with notable colleagues, including Junko Tamiya and Philip Turnbull. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.

Conclusion

Matthew Richard Crittall's contributions to the field of GLP-1 receptor modulation highlight his role as an influential inventor. His work continues to pave the way for advancements in therapeutic applications, showcasing the importance of innovation in medicine.